Cephalon

Cephalon, which is based in Frazer, Pa., said in a statement Tuesday that its board is considering Valeant's unsolicited offer.

Valeant Will Move On if Cephalon Holders Prefer Independence Peter Loftus 2011

Cephalon, which is pleading guilty to one misdemeanor violation of the U.S.

Cephalon Completes Settlement 2008

Cephalon, which is preparing to launch recently approved alcoholism treatment Vivitrol with partner Alkermes, could see earnings come in slightly higher than the Wall Street forecast of 62 cents per share, according to Merrill Lynch analyst Gregg Gilbert.

Four Specialty Pharma Picks For Q1 Upside 2006

Cephalon, which has agreed to be acquired by Teva Pharmaceutical Industries Ltd. for $6.8 billion, said Friday it received a subpoena Wednesday from the Justice Department requesting documents regarding certain promotional practices related to the narcolepsy drugs Nuvigil and Provigil.

Cephalon Gets Second Subpoena in Week Peter Loftus 2011

Cephalon spokeswoman Natalie deVane said the latest subpoena "is narrowly focused on a limited number of promotional efforts that were fully vetted in order to ensure compliance with all applicable laws and regulations."

Cephalon Gets Second Subpoena in Week Peter Loftus 2011

Teva, which recently acquired Cephalon, has said it is cooperating with the commission.

Novartis, J&J Face EU Antitrust Investigation Jeanne Whalen 2011

The commission is already investigating a handful of other drug companies, including France's Les Laboratoires Servier, Teva Pharmaceutical Industries Ltd. of Israel and Cephalon Inc. of the U.S. for possible anticompetitive behavior.

Novartis, J&J Face EU Antitrust Investigation Jeanne Whalen 2011

For the second time in a week, Cephalon Inc. received a subpoena from federal prosecutors seeking information about certain drugs.

Cephalon Gets Second Subpoena in Week Peter Loftus 2011

Cephalon has a compliance program designed to ensure that all its promotional programs are lawful, she said.

Cephalon Gets Second Subpoena in Week Peter Loftus 2011

Earlier this week, Cephalon said it received a subpoena Sept. 23 from the U.S. Attorney's Office in Manhattan seeking records regarding Treanda, a treatment for chronic lymphocytic leukemia.

Cephalon Gets Second Subpoena in Week Peter Loftus 2011